Class information for:
Level 1: NAB PACLITAXEL//CREMOPHOR EL//NEW MAT BIOL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
8196 1209 34.3 80%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
520 14322 SOLID LIPID NANOPARTICLES//NANOSTRUCTURED LIPID CARRIERS//NANOSUSPENSION

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NAB PACLITAXEL Author keyword 29 39% 5% 59
2 CREMOPHOR EL Author keyword 24 41% 4% 46
3 NEW MAT BIOL Address 14 100% 1% 7
4 ORAL PACLITAXEL Author keyword 11 100% 0% 6
5 ABRAXANE Author keyword 9 44% 1% 15
6 ABI 007 Author keyword 7 64% 1% 7
7 ALBUMIN BOUND PACLITAXEL Author keyword 7 50% 1% 10
8 BMS 184476 Author keyword 6 80% 0% 4
9 CREMOPHOR Author keyword 4 31% 1% 12
10 CREMOPHOR R EL Author keyword 4 50% 0% 6

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 NAB PACLITAXEL 29 39% 5% 59 Search NAB+PACLITAXEL Search NAB+PACLITAXEL
2 CREMOPHOR EL 24 41% 4% 46 Search CREMOPHOR+EL Search CREMOPHOR+EL
3 ORAL PACLITAXEL 11 100% 0% 6 Search ORAL+PACLITAXEL Search ORAL+PACLITAXEL
4 ABRAXANE 9 44% 1% 15 Search ABRAXANE Search ABRAXANE
5 ABI 007 7 64% 1% 7 Search ABI+007 Search ABI+007
6 ALBUMIN BOUND PACLITAXEL 7 50% 1% 10 Search ALBUMIN+BOUND+PACLITAXEL Search ALBUMIN+BOUND+PACLITAXEL
7 BMS 184476 6 80% 0% 4 Search BMS+184476 Search BMS+184476
8 CREMOPHOR 4 31% 1% 12 Search CREMOPHOR Search CREMOPHOR
9 CREMOPHOR R EL 4 50% 0% 6 Search CREMOPHOR+R+EL Search CREMOPHOR+R+EL
10 SHR110008 4 75% 0% 3 Search SHR110008 Search SHR110008

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TAXOL METABOLISM 79 82% 4% 46
2 CREMOPHOR EL 56 32% 12% 145
3 NONLINEAR PHARMACOKINETICS 47 49% 6% 71
4 ABI 007 33 61% 3% 35
5 UNBOUND DOCETAXEL 21 85% 1% 11
6 CREMOPHOR FREE 20 32% 4% 52
7 ALBUMIN BOUND PACLITAXEL 19 23% 6% 72
8 TAXOL CONTAINING LIPOSOMES 18 57% 2% 21
9 6 ALPHA HYDROXYTAXOL 18 67% 1% 16
10 UNBOUND PACLITAXEL 17 75% 1% 12

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
nab-Paclitaxel dose and schedule in breast cancer 2015 1 30 70%
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation 2001 595 59 69%
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel - a review 2014 11 51 55%
Paclitaxel and its formulations 2002 474 68 41%
Novel formulations of taxanes: a review. Old wine in a new bottle? 2006 170 76 50%
nab-Paclitaxel mechanisms of action and delivery 2013 36 63 33%
Albumin-bound formulation of paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer 2009 160 56 32%
Liposomal paclitaxel formulations 2012 47 94 43%
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy 2003 218 166 43%
DRUG-THERAPY - PACLITAXEL (TAXOL) 1995 1263 79 27%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NEW MAT BIOL 14 100% 0.6% 7
2 PHARMACEUT ANAL TOXICOL 3 35% 0.7% 8
3 SLOTERVAART HOSP 3 13% 1.9% 23
4 DRUG TOXICOL 3 11% 2.2% 26
5 MED ONCOL CLIN PHARMACOL 3 45% 0.4% 5
6 HOSP PHARM CLIN PHARMACOL 2 36% 0.3% 4
7 GENOME QUEBEC MONTREAL HEART 2 43% 0.2% 3
8 UNIDAD ONCOL MED 2 33% 0.3% 4
9 SECT BIOMED ANAL 1 38% 0.2% 3
10 DANIEL DE HOED KLIN 1 100% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000168734 METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL
2 0.0000147884 HYPERSENSITIVITY REACTIONS//HYPERSENSITIVITY REACTION//CARBOPLATIN HYPERSENSITIVITY
3 0.0000132904 TAXACEAE//TAXOIDS//TAXOID
4 0.0000125695 LIPID NANOCAPSULES//U1066//U646
5 0.0000116953 HEMATOL ONCOLWINSHIP CANC//MICROTUBULE ACTIVE DRUGS//PHARMACOLRAMMELKAMP EDUC
6 0.0000116418 CANCER NANOTECHNOLOGY//NANOSCI NANOENGN INITIAT NUSNNI//CHEMOTHERAPEUTIC ENGINEERING
7 0.0000074790 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY//GOSHAJINKIGAN//CIPN
8 0.0000074663 BOVINE SERUM ALBUMIN NANOPARTICLES//HUMAN SERUM ALBUMIN NANOPARTICLES//COACERVATION METHOD
9 0.0000062729 VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER
10 0.0000057621 PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN